

## MOG-antibody associated disease

### THURSDAY, 7 MARCH 2019

- 08.30 - 08.45**                      **Welcome from ECTRIMS President**  
*B. Hemmer (Munich, DE)*
- 08.45 - 09.00**                      **Introduction – State of the art / unmet needs**  
*S. Vukusic (Lyon, FR)*
- 09.00 - 10.15**                      **Session 1: From immunology to pathology of MOG-Ab associated disease**  
Chair persons: C. Lucchinetti (Rochester, US), F. Brilot (Sydney, AU)
- 09.00                                  History and update on the detection methods  
*M. Reindl (Innsbruck, AT)*
- 09.15                                  Animal models of MOG autoimmunity  
*E. Meinl (Munich, DE)*
- 09.30                                  Imaging the in vivo effects of human MOG antibodies  
*B. Hemmer (Munich, DE)*
- 09.45                                  Pathology of MOG-Ab associated disease  
*H. Lassmann (Vienna, AT)*
- 10.00                                  Which pieces are missing in our understanding of MOG-Ab associated disease?  
*T. Derfuss (Basel, CH)*
- 10.15 - 10.45**                      **Coffee break**
- 10.45 - 11.30**                      **Roundtable/Panel discussion 1**
- 11.30 - 12.45**                      **Session 2: The clinical spectrum and prognosis of MOG-Ab associated disease**  
Chair persons: S. Pittock (Rochester, US), M. I. Leite (Oxford, UK)
- 11.30                                  Prevalence of MOG-Ab (Control donors/ NMO spectrum / children / before onset, different countries)  
*J. De Sèze (Strasbourg, F)*

- 11.45 Typical spectrum in adults  
*A.-K. Pröbstel (San Francisco, US)*
- 12.00 Typical spectrum in children  
*K. Deiva (Paris, FR)*
- 12.15 Atypical presentations  
*K. Fujihara (Fukushima, JP)*
- 12.30 Clinical unmet needs (cognition, vaccination, pregnancy...)  
*M.P. Amato (Florence, IT)*
- 12.45 - 14.00 Lunch**
- 14.00 - 14.45 Session 2: The clinical spectrum and prognosis of  
MOG-Ab associated disease (continued)**  
Chair persons: S. Pittock (Rochester, US), M. I. Leite (Oxford, UK)
- 14.00 Prognosis in adults  
*H.J. Kim (Goyang, KR)*
- 14.15 Prognosis in children  
*T. Chitnis (Boston, USA)*
- 14.30 Are MOG-Ab a disease biomarker?  
*P. Waters (Oxford, UK)*
- 14.45 – 15.30 Roundtable/Panel discussion 2**
- 15.30 - 16.00 Coffee break**
- 16.00 - 17.15 Session 3: Non clinical evaluation of MOG-Ad associated disorder**  
Chair persons: A. Traboulsee (Vancouver, CA), A. Petzold (London, UK)
- 16.00 CSF immunology of MOG-Ab associated disease  
*S. Jarius (Heidelberg, DE)*
- 16.15 Exploring the visual pathways (OCT-MRI)  
*F. Paul (Berlin, DE)*
- 16.30 Conventional brain MRI  
*J. Palace (Oxford, UK)*

- 16.45 Conventional spinal Cord MRI  
*D. Sato (Porto Alegre, BR)*
- 17.00 Unmet needs (advance and future of imaging MOG)  
*O. Ciccarelli (London, UK)*
- 17.15 - 18.00 Roundtable/Panel discussion 3**
- 18.00 - 18.15 Wrap-up Day 1**  
*T. Derfuss (Basel, CH)*
- 19.15 **ECTRIMS Focused Workshop Dinner**

## **FRIDAY, 8 MARCH 2019**

- 08.30 - 10.00 Session 4: How should we treat MOG-Ab associated disease**  
Chair persons: B. Weinshenker (Rochester, US), R. Hintzen (Rotterdam, NL)
- 08.30 Attacks  
*I. Kleiter (Bochum, DE)*
- 08.45 Immediately after the 1<sup>st</sup> episode - YES  
*M. Tintore (Barcelona, ES)*
- 09.00 Immediately after the 1<sup>st</sup> episode - NO  
*E. Waubant (San Francisco, US)*
- 09.15 With MS disease-modifying treatment  
*R. Marignier (Lyon, FR)*
- 09.30 With NMO treatment  
*A. Jacob (Liverpool, UK)*
- 09.45 Treatment unmet needs (evaluation of treatment - trial design)  
*B. Weinshenker (Rochester, US)*
- 10.00 - 10.45 Roundtable/Panel discussion 4**
- 10.45 - 11.15 Coffee break**

**11.15 - 12.00**

**Meeting summary**

*Session 1: B. Hemmer (Munich, DE)*

*Session 2: S. Vukusic (Lyon, FR)*

*Session 3: T. Derfuss (Basel, CH)*

*Session 4: R. Marignier (Lyon, FR)*

**12.00 - 13.00**

**Roundtable/Panel discussion 5**

**13.00**

**End of the workshop / Lunch and individual departure**